The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid

International Journal of Biological Markers

Volumn 26, Issue 3, 2011, Pages 141-152

  Nolen, Brian M ^a,b   Lokshin, Anna E ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Early detection; Ovarian cancer; Pancreatic cancer; Screening; Serum biomarkers; Urine biomarkers

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; HUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; SAMPLING; SERUM; URINALYSIS; URINE; ADULT; AGED; BLOOD; BREAST NEOPLASMS; DIAGNOSTIC TEST; EARLY CANCER DIAGNOSIS; FEMALE; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; YOUNG ADULT;

EID: 80053378619     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8613     Document Type: Review

References (93)

1. Koomen JM, Li D, Xiao LC, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005; 4: 972-81.
2. Teisner B, Davey MW, Grudzinskas JG. Interaction between heparin and plasma proteins analysed by crossed immunoelectrophoresis and affinity chromatography. Clin Chim Acta 1983; 127: 413-7.
3. Coon JJ, Zürbig P, Dakna M, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008; 2: 964-73.
4. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ ionization time-of-flight mass spectrometry. Kidney Int 2004; 65: 323-32.
5. Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics 2008; 7: 1850-62.
6. Ye B, Skates S, Mok SC, et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006; 12: 432-41.
7. Schiffer E, Mischak H, Novak J. High resolution proteome/ peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 2006; 6: 5615-27.
8. Vestergaard P, Leverett R. Constancy of urinary creatinine excretion. J Lab Clin Med 1958; 51: 211-8.
9. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and challenges. Proteomics 2005; 5: 1033-42.
10. Cole LA, Schwartz PE, Wang YX. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers. Gynecol Oncol 1988; 31: 82-90.
11. Plebani M, Navaglia F, Basso D, et al. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. Anticancer Res 1996; 16: 3833-8.
12. Walker R, Crebbin V, Stern J, Scudder S, Schwartz P. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Anticancer Res 1994; 14: 1703-9.
13. Hellstrom I, Heagerty PJ, Swisher EM, et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010; 296: 43-8.
14. Badgwell D, Lu Z, Cole L, et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 2007; 106: 490-7.
15. Anderson NS, Bermudez Y, Badgwell D, Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 2009; 112: 60-7.
16. Drenberg CD, Saunders BO, Wilbanks GD, et al. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol 2010; 117: 117-24.
17. Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 2010; 8: 58.
18. Petri AL, Simonsen AH, Hogdall E, et al. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin Appl 2010; 4: 304-14.
19. Petri AL, Simonsen AH, Yip TT, et al. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009; 88: 18-26.
20. Slupsky CM, Steed H, Wells TH, et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010; 16: 5835-41.
21. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010; 117: 440-5
22. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159-66.
23. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-66.
24. Menon U, Jacobs IJ. Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 2001; 11 (Suppl 1): 3-6.
25. MacDonald ND, Rosenthal AN, Jacobs IJ. Screening for ovarian cancer. Ann Acad Med Singapore 1998; 27: 676-82.
26. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402-8.
27. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40-6.
28. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228 e1-6.
29. American Cancer Society Statistics. (Accessed at www. cancer.org.).
30. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003; 138: 168-75.
31. Kopans DB. Clinical breast examination for detecting breast cancer. JAMA. 2000; 283: 1688; author reply 1689.
32. Baker LH. Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin 1982; 32: 194-225.
33. Foxcroft LM, Evans EB, Joshua HK, Hirst C. Breast cancers invisible on mammography. Aust N Z J Surg 2000; 70: 162-7.
34. Bartsch R, Wenzel C, Pluschnig U, et al. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 2006; 6: 81.
35. Gion M, Mione R, Becciolini A, et al. Relationship between cytosol TPS, TPA and cell proliferation. Int J Biol Markers 1994; 9: 109-14.
36. Molina R, Agusti C, Filella X, et al. Studyof a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol 1994; 15: 318-25.
37. Fuckar D, Dekanic A, Stifter S, et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 2006; 14: 49-55.
38. Leonard GD, Low JA, Berman AW, Swain SM. CA 125 elevation in breast cancer: a case report and review of the literature. Breast J 2004; 10: 146-9.
39. Danforth DN, Jr, Sgagias MK. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 1993; 53: 1538-45.
40. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995; 1: 1031-4.
41. Ohuchi N, Matoba N, Taira Y, et al. Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4. Gan To Kagaku Ryoho 1988; 15: 2767-72.
42. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family--a novel panel of cancer biomarkers. Tumour Biol 2002; 23: 185-92.
43. Kim Y, Koo I, Jung BH, Chung BC, Lee D. Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics 2010; 11 (Suppl 2): S4.
44. Nam H, Chung BC, Kim Y, Lee K, Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 2009; 25: 3151-7.
45. Frickenschmidt A, Frohlich H, Bullinger D, et al. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008; 13: 435-49.
46. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010; 19: 729-37.
47. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2008; 100: 898-905.
48. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev 2009; 18: 74-9.
49. Pories SE, Zurakowski D, Roy R, et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008; 17: 1034-42.
50. Umemori Y, Ohe Y, Kuribayashi K, et al. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers. Clin Chim Acta 2010; 411: 1894-9.
51. Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res 2008; 10: R32.
52. Jesneck JL, Mukherjee S, Yurkovetsky Z, et al. Do serum biomarkers really measure breast cancer? BMC Cancer 2009; 9: 164.
53. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003; 27: 87-93.
54. Lowenfels AB, Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin North Am 2002; 16: 1-16.
55. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004; 59: 99-111.
56. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-79.
57. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266-70.
58. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-8.
59. Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol 1999; 34: 833-44.
60. Hustinx SR, Cao D, Maitra A, et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 2004; 3: 1254-61.
61. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12: 442-6.
62. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000; 89: 83-8.
63. Zhou W, Sokoll LJ, Bruzek DJ, et al. Identifying markers for pancreatic cancer by gene expression analysis. Cance Epidemiol Biomarkers Prev 1998; 7: 109-12.
64. Moniaux N, Chakraborty S, Yalniz M, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008; 98: 1540-7.
65. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-6.
66. Hayak awa T, Naruse S, Kitagawa M, et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol 1999; 25: 23-9.
67. Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008; 5: e123.
68. Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011; 17: 805-16.
69. Dianxu F, Shengdao Z, Tianquan H, et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002; 25: 336-41.
70. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-13.
71. Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology; 138: 949-57 e1-7.
72. Allen PJ, Qin LX, Tang L, Klimstra D, Brennan MF, Lokshin A. Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg 2009; 250: 754-60.
73. Haab BB, Porter A, Yue T, et al. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg; 251: 937-45.
74. Motoo Y, Watanabe H, Yamaguchi Y, et al. Urinary gonadotropin peptide in patients with cancer of digestive organs. Anticancer Res 1996; 16: 2041-8.
75. Weeks ME, Hariharan D, Petronijevic L, et al. Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proteomics Clin Appl 2008; 2: 1047-57.
76. Szajda SD, Snarska J, Jankowska A, Puchalski Z, Zwierz K. Isoenzymes A and B of N-acetyl-beta-D-hexosaminidase in serum and urine of patients with pancreatic cancer. Hepatogastroenterology 2008; 55: 695-8.
77. Szajda SD, Waszkiewicz N, Chojnowska S, Zwierz K. Carbohydrate markers of pancreatic cancer. Biochem Soc Trans 2011; 39: 340-3.
78. Yamaguchi K, Nakamura M, Shirahane K, et al. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas. Dig Liver Dis 2005; 37: 190-4.
79. Ruggiero A, Villa CH, Bander E, et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 2010; 107: 12369-74.
80. Heavner DL, Morgan WT, Sears SB, Richardson JD, Byrd GD, Ogden MW. Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines. J Pharm Biomed Anal 2006; 40: 928-42.
81. Suwazono Y, Åkesson A, Alfvén T, Järup L, Vahter M. Creatinine versus specific gravity-adjusted urinary cadmium concentrations. Biomarkers 2005; 10: 117-26.
82. Alessio L, Berlin A, Dell'Orto A, Toffoletto F, Ghezzi I. Reliability of urinary creatinine as a parameter used to adjust values of urinary biological indicators. Int Arch Occup Environ Health 1985; 55: 99-106.
83. Curtis G, Fogel M. Creatinine excretion: diurnal variation and variability of whole and part-day measures. A methodologic issue in psychoendocrine research. Psychosom Med 1970; 32: 337-50.
84. Hsu J, Johansen KL, Hsu CY, Kaysen GA, Chertow GM. Higher serum creatinine concentrations in black patients with chronic kidney disease: beyond nutritional status and body composition. Clin J Am Soc Nephrol 2008; 3: 992-7.
85. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-9.
86. Jatlow P, McKee S, O'Malley SS. Correction of urine cotinine concentrations for creatinine excretion: is it useful? Clin Chem 2003; 49: 1932-4.
87. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010; 78: 486-94.
88. Al-Aloul M, Jackson M, Bell G, Ledson M, Walshaw M. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros 2007; 6: 41-7.
89. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15-20.
90. Neubert A, Remer T. The impact of dietary protein intake on urinary creatinine excretion in a healthy pediatric population. J Pediatr 1998; 133: 655-9
91. Penner SB, Bernstein KN, Fine A. Changes in endogenous creatinine clearance in man on a controlled protein diet: Effect of route of administration of a protein load. Clin Invest Med 1990; 13: 233-6.
92. Tan KHV, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 819-23.
93. Worsfold M, Davie MWJ, Haddaway MJ. Age-related changes in body composition, hydroxyproline, and creatinine excretion in normal women. Calcif Tissue Int 1999; 64: 40-4.